Cathepsin-k expression in pulmonary lymphangioleiomyomatosis.

Department of Pathology, University of Verona, Verona, Italy.
Modern Pathology (Impact Factor: 6.36). 01/2009; 22(2):161-6. DOI: 10.1038/modpathol.2008.189
Source: PubMed

ABSTRACT Lymphangioleiomyomatosis is a rare and progressive lung cystic disease, caused by the infiltration of lung parenchyma by mesenchymal cells characterized by co-expression of contractile proteins and melanocytic markers. The pathogenesis of lymphangioleiomyomatosis is determined by mutations affecting tuberous sclerosis complex (TSC) genes, with eventual deregulation of the Rheb/mTOR/p70S6K pathway, and the potential therapeutic activity of mTOR inhibitors is currently under investigation. To better understand the molecular mechanisms involved in the pathogenesis of lymphangioleiomyomatosis, we investigated the expression of cathepsin-k (a papain-like cysteine protease with high matrix-degrading activity). The rationale of this choice was based on the recent demonstration that mTOR inhibitors can regulate major functional activities of osteoclasts, including the expression of cathepsin-k. The immunohistochemical study included 12 cases of lymphangioleiomyomatosis. Twelve angiomyolipomas and several lung diseases (sarcoidosis, organizing pneumonia, usual interstitial pneumonia, emphysema) were investigated as controls. In all lymphangioleiomyomatosis cases, strong cathepsin-k immunoreactivity was demonstrated, restricted to lymphangioleiomyomatosis cells. Similar expression levels were observed in renal angiomyolipomas. These observations extend the knowledge regarding the immunophenotypic profile of lymphangioleiomyomatosis cells, and provide a useful new marker for diagnosis in difficult cases (eg, in small transbronchial biopsies). The strong expression of such a potent papain-like cysteine protease in lymphangioleiomyomatosis cells can significantly contribute to the progressive remodelling of lung parenchyma observed in this deadly disease, with eventual formation of lung cysts. It is possible to speculate that mTOR inhibitors may exert part of their action by limiting the destructive remodelling of lung structure.


Available from: Maurizio Pea, Jun 14, 2015
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Many soft tissue tumors of childhood lack obvious differentiation toward a defined mesenchymal tissue type or have a phenotype that does not correspond to any defined normal tissue. These challenging tumors are currently regarded as neoplasms of uncertain differentiation. Nonetheless, there have been great strides in the understanding of their pathologic and genetic features and biologic underpinnings. The application of new genetic information to the pathologic diagnosis among this group of tumors is an emerging area in diagnostic pediatric pathology. This article reviews the clinicopathologic features of tumors of uncertain and/or miscellaneous origin, with an emphasis on the unique aspects of these neoplasms in children and adolescents, use of diagnostic adjuncts, and differential diagnosis.
    Pediatric and Developmental Pathology 01/2012; 15(1 Suppl):267-305. DOI:10.2350/11-08-1079-PB.1 · 0.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rationale. Sirolimus therapy stabilizes lung function and reduces the size of chylous effusions and lymphangioleiomyomas in patients with lymphangioleiomyomatosis. Objectives. To determine whether sirolimus has beneficial effects on lung function, cystic areas and adjacent lung parenchyma, whether these effects are sustained, and sirolimus is well tolerated by patients. Methods. Lung function decline over time, lung volume occupied by cysts (cyst score), and lung tissue texture in the vicinity of the cysts, were quantified with a computer-aided diagnosis system, in 38 patients. Then we compared cyst scores from the last study off sirolimus with studies done on sirolimus therapy. In 12 patients, we evaluated rates of change in lung function and cyst scores off and on sirolimus. Measurements and results. Sirolimus reduced yearly declines in FEV1 (-2.3±0.1 versus 1.0±0.3 % predicted, p<0.001) and DLCO (-2.6±0.1 versus 0.9±0.2 % predicted, p<0.001). Cyst scores 1.2±0.8 years (30.5±11.9 %), and 2.5±2 years (29.7±12.1 %) after initiating sirolimus were not significantly different from pre-treatment values (28.4±12.5 %). In 12 patients, followed for five years, a significant reduction in rates of yearly decline in FEV1 (-1.4±0.2 versus 0.3±0.4 % predicted, p=0.025) was observed. Analyses of 104 computed tomography scans showed a non-significant (p=0.23) reduction in yearly rates of change of cyst scores (1.8±0.2 versus 0.3±0.3 %, p=0.23), and lung texture features. Despite adverse events, most patients were able to continue sirolimus therapy. Conclusions. Sirolimus therapy slowed down lung function decline and increase in cystic lesions. Most patients were able to tolerate sirolimus therapy.
    American Journal of Respiratory and Critical Care Medicine 10/2014; DOI:10.1164/rccm.201405-0918OC · 11.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: PEComas are mesenchymal tumors composed of histologically and immunohistochemically distinctive perivascular epithelioid cells which are characterized by the coexpression of muscle and melanogenesis markers. This group of lesions includes angiomyolipoma, clear-cell “sugar” tumor of the lung and extrapulmonary sites, lymphangioleiomyomatosis, clear-cell myomelanocytic tumor of the falciform ligament/ligamentum teres and rare clear-cell tumors of other anatomical sites. In the genitourinary tract PEComas have been described in the kidney, bladder, prostate, testis and urethra. Although most PEComas behave as benign tumors, some are potentially malignant and criteria for malignancy have been suggested for both and renal and extrarenal lesions. Recently the expression of cathepsin K has been demonstrated in a large number of PEComas and has been proposed as a relatively specific marker to distinguish these proliferations from the majority of human cancers. In addition, a distinctive subset of PEComas harboring TFE3 gene fusions have been reported, giving rise to a possible relationship between them and MiTF/TFE family translocation renal cell carcinomas. The genetic alterations of tuberous sclerosis complex that promote activation of the mTOR pathway have been identified in PEComas. Therapy with mTORC1 inhibitors has been shown to be effective in some cases.
    Seminars in Diagnostic Pathology 02/2015; 32(2). DOI:10.1053/j.semdp.2015.02.006 · 1.80 Impact Factor